Irinotecan Hydrochloride Liposome Injection (II)

DRUG2 trials

Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

Conditions

Biliary Tract CancerGastric CancerStomach Neoplasms

Phase 2

Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer

RecruitingNCT07797816

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBiliary Tract Cancer

Start: 2026-01-08End: 2028-12-31Target: 31Updated: 2026-09-01

A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer

Not yet recruitingNCT07819019

Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterGastric Cancer, Stomach Neoplasms

Start: 2026-10-01End: 2030-10-01Target: 20Updated: 2026-09-14